mitoxantrone has been researched along with Sepsis in 10 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features." | 9.14 | Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. ( Alino, K; Blackford, A; Bolaños-Meade, J; Carraway, HE; Doyle, LA; Gore, SD; Greer, JM; Jones, RJ; Karp, JE; Levis, MJ; McDevitt, MA; Seung, AH; Smith, BD; Wright, JJ, 2010) |
| "To evaluate the activity and tolerance of docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor (G-CSF) as front-line treatment in patients with metastatic breast cancer (MBC)." | 9.09 | Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. ( Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J, 2001) |
| " In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features." | 5.14 | Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. ( Alino, K; Blackford, A; Bolaños-Meade, J; Carraway, HE; Doyle, LA; Gore, SD; Greer, JM; Jones, RJ; Karp, JE; Levis, MJ; McDevitt, MA; Seung, AH; Smith, BD; Wright, JJ, 2010) |
| "To evaluate the activity and tolerance of docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor (G-CSF) as front-line treatment in patients with metastatic breast cancer (MBC)." | 5.09 | Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. ( Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J, 2001) |
| "A 64-year-old man with acute myelogenous leukemia (FAB classification, M7) in remission received consolidation chemotherapy with mitoxantrone/cytosine arabinoside." | 4.85 | [Bacillus cereus sepsis and subarachnoid hemorrhage following consolidation chemotherapy for acute myelogenous leukemia]. ( Gondo, H; Kawatani, E; Kishikawa, Y; Kuwahara, N; Matsuishi, E; Mori, D; Osoegawa, K; Sankoda, C, 2009) |
| " Immunoblot analysis revealed iNOS protein expression in four out of six failing hearts from septic patients, whereas no iNOS-protein expression was detected in either non-failing human hearts (n = 6) or failing hearts due to IDC (n = 9), ischemic heart disease (IHD, n = 7), Becker muscular dystrophy (BMD, n = 2) and mitoxantrone-induced toxic cardiomyopathy TCM, n = 1)." | 3.69 | Expression of inducible nitric oxide synthase in failing and non-failing human heart. ( Bleese, NM; Förstermann, U; Nüssler, AK; Scholz, H; Stein, B; Thoenes, M; Tracey, WR, 1996) |
| "Outcome of adults with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission (CR) or who relapse soon after initial response is poor." | 2.72 | Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). ( Adamczyk-Cioch, M; Dmoszynska, A; Giebel, S; Holowiecki, J; Jakubas, B; Krawczyk-Kulis, M; Lewandowski, K; Nowak, K; Palynyczko, G; Skotnicki, A, 2006) |
| " The maximal acceptable dosage of mitoxantrone was 10 mg/m2 x 2 due to serious hematologic toxicity." | 2.69 | Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. ( Berinstein, NL; Franssen, E; Haq, R; Sawka, CA, 1999) |
| "67 patients with relapsed or resistant multiple myeloma were randomized to receive either VAD (vincristine, doxorubicin, dexamethasone) or MOD (mitozantrone, vincristine, dexamethasone)." | 2.68 | A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. ( Cawley, JC; Davies, JM; Newland, AC; Pearce, R; Phillips, JK; Reilly, JT; Sherlaw-Johnson, C, 1995) |
| "Bacterial bloodstream infections were the most frequent followed by respiratory tract infections." | 1.91 | Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. ( Boeckh, M; Cheng, GS; Chung, EL; Delaney, C; Halpern, AB; Hill, JA; Huebner, EM; Kiem, ES; Kimball, LE; Leisenring, WM; Liu, C; Pergam, SA; Schonhoff, KG; Walter, RB; Walti, CS; Xie, H, 2023) |
| "Treatment with ciprofloxacin and gamma-globulin dramatically improved the patient's clinical features." | 1.32 | [Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient]. ( Komatsu, N; Mori, M; Nagai, T; Obara, Y; Ohmine, K; Ozawa, K; Toshima, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Walti, CS | 2 |
| Halpern, AB | 2 |
| Xie, H | 2 |
| Kiem, ES | 2 |
| Chung, EL | 2 |
| Schonhoff, KG | 2 |
| Huebner, EM | 2 |
| Delaney, C | 2 |
| Liu, C | 2 |
| Pergam, SA | 2 |
| Cheng, GS | 2 |
| Kimball, LE | 2 |
| Leisenring, WM | 2 |
| Boeckh, M | 2 |
| Walter, RB | 2 |
| Hill, JA | 2 |
| Kawatani, E | 1 |
| Kishikawa, Y | 1 |
| Sankoda, C | 1 |
| Kuwahara, N | 1 |
| Mori, D | 1 |
| Osoegawa, K | 1 |
| Matsuishi, E | 1 |
| Gondo, H | 1 |
| Karp, JE | 1 |
| Blackford, A | 1 |
| Smith, BD | 1 |
| Alino, K | 1 |
| Seung, AH | 1 |
| Bolaños-Meade, J | 1 |
| Greer, JM | 1 |
| Carraway, HE | 1 |
| Gore, SD | 1 |
| Jones, RJ | 1 |
| Levis, MJ | 1 |
| McDevitt, MA | 1 |
| Doyle, LA | 1 |
| Wright, JJ | 1 |
| Apostolidou, E | 1 |
| Estey, E | 1 |
| Cortes, J | 1 |
| Garcia-Manero, G | 1 |
| Faderl, S | 1 |
| Thomas, D | 1 |
| Tsimberidou, A | 1 |
| Kantarjian, H | 1 |
| Giles, FJ | 1 |
| Obara, Y | 1 |
| Nagai, T | 1 |
| Mori, M | 1 |
| Ohmine, K | 1 |
| Toshima, M | 1 |
| Komatsu, N | 1 |
| Ozawa, K | 1 |
| Giebel, S | 1 |
| Krawczyk-Kulis, M | 1 |
| Adamczyk-Cioch, M | 1 |
| Jakubas, B | 1 |
| Palynyczko, G | 1 |
| Lewandowski, K | 1 |
| Dmoszynska, A | 1 |
| Skotnicki, A | 1 |
| Nowak, K | 1 |
| Holowiecki, J | 1 |
| Phillips, JK | 1 |
| Sherlaw-Johnson, C | 1 |
| Pearce, R | 1 |
| Davies, JM | 1 |
| Reilly, JT | 1 |
| Newland, AC | 1 |
| Cawley, JC | 1 |
| Thoenes, M | 1 |
| Förstermann, U | 1 |
| Tracey, WR | 1 |
| Bleese, NM | 1 |
| Nüssler, AK | 1 |
| Scholz, H | 1 |
| Stein, B | 1 |
| Haq, R | 1 |
| Sawka, CA | 1 |
| Franssen, E | 1 |
| Berinstein, NL | 1 |
| Alexopoulos, A | 1 |
| Kouroussis, C | 1 |
| Malamos, N | 1 |
| Kakolyris, S | 1 |
| Kalbakis, K | 1 |
| Kosmas, C | 1 |
| Mavroudis, D | 1 |
| Agelaki, S | 1 |
| Vlachonicolis, J | 1 |
| Sarra, E | 1 |
| Rigatos, G | 1 |
| Georgoulias, V | 1 |
1 review available for mitoxantrone and Sepsis
| Article | Year |
|---|---|
[Bacillus cereus sepsis and subarachnoid hemorrhage following consolidation chemotherapy for acute myelogenous leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bacillaceae Infections; Bacillus cereus; Cytarabine; | 2009 |
6 trials available for mitoxantrone and Sepsis
| Article | Year |
|---|---|
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantatio | 2010 |
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Human | 2003 |
Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease- | 2006 |
A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance; F | 1995 |
Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; D | 1999 |
Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast | 2001 |
3 other studies available for mitoxantrone and Sepsis
| Article | Year |
|---|---|
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
[Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Cytarabine; Ec | 2004 |
Expression of inducible nitric oxide synthase in failing and non-failing human heart.
Topics: Animals; Cardiomyopathies; Cardiomyopathy, Dilated; Cell Line; Cyclic GMP; Gene Expression; Heart Fa | 1996 |